ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P10-16 New Drug-Related Prior Authorization Criteria for Gattex
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 08, 2016
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 2981 - 2990 လၢ 4179 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P16-16 Blue Cross Contracts with SecureCare to Manage the Chiropractic Network
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 22, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P4-16 New Drug-Related Prior Authorization Criteria for Myalept
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 08, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P33-16 New Drug-Related Prior Authorization Criteria with Quantity Limit for Northera
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 27, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P11-16 New Drug-Related Prior Authorization Criteria: Idiopathic P ulmonary Fibrosis Prior Authorization with Quantity Limit Criteria: Esbriet ® and Ofev ®
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 08, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P50-17 Provider Data Accuracy and Identified Lack of Claim Submissions
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 25, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P30-16 New Prior Authorization Requirement for Lyme Disease: Diagnostic Testing and Intravenous Antibiotic Therapy
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 07, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P14-16 Addition of Lazanda ® to Existing Drug-Related Prior Authorization with Quantity Limit Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 29, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P49-16 New Drug-Related Prior Authorization Criteria with Quantity Limit for Zavesca
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 27, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P24-16 Providers will see a change in our Prior Authorization Process for Government Products
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 01, 2016